Blueprint Medicines Closes Acquisition of Lengo Therapeutics.

MANews-(C)2009-2022

US-based precision therapy company Blueprint Medicines Corp. (NASDAQ: BPMC) has completed the acquisition of Lengo Therapeutics, the company said.

This deal includes Lengo's lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations.

An investigational new drug application for LNG-451 was submitted to the US Food and Drug Administration by Lengo Therapeutics in December 2021.

As previously reported, under the terms of the agreement...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT